We are live on ! Find out more
EDIT icon

Editas Medicine

195 hedge funds and large institutions have $51M invested in Editas Medicine in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 61 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $668K | Put options by funds: $339K

6% less funds holding

Funds holding: 207195 (-12)

8.81% less ownership

Funds ownership: 61.84%53.03% (-8.8%)

21% less capital invested

Capital invested by funds: $64.8M → $51M (-$13.8M)

28% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 61

32% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 34

Holders
195
Holders Change
-12
Holders Change %
-5.8%
% of All Funds
2.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
44
Reduced
61
Closed
34
Calls
$668K
Puts
$339K
Net Calls
+$329K
Net Calls Change
+$321K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$331K -$3.62M -2,461,597 -90%
HWAM
27
Hennion & Walsh Asset Management
New Jersey
$299K -$15.1K -10,298 -4%
SFI
28
Susquehanna Fundamental Investments
Pennsylvania
$282K -$42.6K -28,933 -11%
Marshall Wace
29
Marshall Wace
United Kingdom
$281K +$357K +242,376 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$271K -$13.9K -9,425 -4%
Raymond James Financial
31
Raymond James Financial
Florida
$229K -$61K -41,501 -17%
GAA
32
Green Alpha Advisors
Colorado
$213K +$106K +72,275 +65%
Mirae Asset Global ETFs Holdings
33
Mirae Asset Global ETFs Holdings
Hong Kong
$196K -$11.7K -7,981 -5%
Los Angeles Capital Management
34
Los Angeles Capital Management
California
$188K +$93.1K +63,291 +64%
IC
35
IEQ Capital
California
$186K +$200K +135,736 +551%
Wells Fargo
36
Wells Fargo
California
$175K -$51.7K -35,147 -19%
Barclays
37
Barclays
United Kingdom
$164K -$58.9K -40,054 -22%
AllianceBernstein
38
AllianceBernstein
Tennessee
$155K
Simplex Trading
39
Simplex Trading
Illinois
$155K +$141K +95,525 +247%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$144K -$24.8K -16,867 -12%
Citadel Advisors
41
Citadel Advisors
Florida
$135K -$1.18M -805,335 -87%
Invesco
42
Invesco
Georgia
$101K -$19.5K -13,262 -13%
Cambridge Investment Research Advisors
43
Cambridge Investment Research Advisors
Iowa
$99K -$928 -631 -0.7%
SEI Investments
44
SEI Investments
Pennsylvania
$96.5K
Prudential Financial
45
Prudential Financial
New Jersey
$92.7K -$172K -117,040 -59%
TI
46
Tidal Investments
Wisconsin
$87.8K -$9.16K -6,230 -8%
IIM
47
INTECH Investment Management
Florida
$86.5K +$49.5K +33,661 +82%
TYCC
48
Texas Yale Capital Corp
Florida
$81.2K
Citigroup
49
Citigroup
New York
$73.3K -$52.9K -35,946 -36%
Thrivent Financial for Lutherans
50
Thrivent Financial for Lutherans
Minnesota
$71K

EDIT Hedge Fund Activity: Q1 2025 in Review

195 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2025, worth a combined $51M — down 21% from $64.8M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EDIT and 23 opened new positions — a net loss of 11 holders — while 61 trimmed existing stakes and 44 added.

The largest buyer was UBS AM, adding an estimated $2.1M. The largest seller was Millennium Management, cutting an estimated $3.62M.

  • 195 institutional investors held Editas Medicine (EDIT) as of Q1 2025, down from 207 in Q4 2024.
  • Funds reported $51M of Editas Medicine stock for Q1 2025, down 21% quarter-over-quarter.
  • 23 funds opened new Editas Medicine positions in Q1 2025 and 34 closed out, a net change of -11 holders.
  • The largest Editas Medicine buyer in Q1 2025 was UBS AM, an estimated $2.1M added.
  • The largest Editas Medicine seller in Q1 2025 was Millennium Management, an estimated $3.62M sold.

Based on aggregated 13F filings for Q1 2025.